terminal half-life

This period is usually at least three times the terminal half-life of the drug.

The mean terminal half‑life of bevacizumab ranged approximately from 5 to 15 days.

The terminal half-life ranged from 4 to 6 hours.

Differences in elimination (clearance and terminal half-life) should be compared as well.

The mean plasma terminal half-life of lumiracoxib is approximately four hours.

The apparent terminal half-life was approximately 12 hours following a single dose in the fed state.

Perampanel has a prolonged terminal half-life in humans of approximately 105 hours.

Dipyridamole is metabolized in the liver and has a terminal half-life of 10 hours.

The mean terminal half-life was similar between pediatric and adult patients and ranged from 15.7 to 22.5 hours.

However, cholestasis due to terbinafine appears to be more chronic, possibly because the drug has a very long terminal half-life.

Plasma clearance is reported to be bi-phasic and the terminal half-life may be longer than 7 days.

A drug measurement methodology insufficiently sensitive or reliable to determine blood concentrations to at least three terminal half-lives.

Elimination- identify the route(s), percent of elimination and terminal half-life (T½ ).

However, as noted above, the terminal half-life of THC can be much longer with considerable individual variability111.

This glycoprotein has a longer terminal half-life, meaning it is possible to administer it less frequently.

At the same dosages, the mean terminal half-life ranged from 23 minutes in rats to approximately 3 hours in monkeys.

It is notable however, that the terminal half-life of the product was consistently almost twice that of the previous experiment.

It is probably safe to say that the terminal half-life of THC averages at least a week and could be considerably longer.

Absolute bioavailability of lumiracoxib was approximately 74% and the terminal half-life was approximately 4 hours.

The initial phase half-life is approximately 1 minute and the terminal half-life is approximately 15 minutes.

Elimination is biphasic with a half-life of 6-10 minutes and a terminal half-life of approximately 30 minutes.

Thus drugs with a very short terminal half-life, including artemisinin derivatives, carry a lower risk of selecting resistant parasites than longer acting drugs.

The average terminal half-lives of DHD and dydrogesterone vary between 14-17 and 5-7 hours, respectively.

The apparent terminal half-life (t1/2) of pantoprazole is increased by approximately 23% with the magnesium tablets as compared to the sodium tablets.

The terminal half-life was approximately 2-3 days in all ocular matrices, and there was rapid penetration into retinal tissues.